Skip to content

View Spec Sheet

open_in_new
  1. Shop all
  2. Monoclonal

SMC-405

Cav3.1 Antibody, Clone N178A/9

Cannot supply to this region.

SKU:
SMC-405
Additional Names:
Voltage-dependent T-type calcium channel subunit alpha-1G, Cav3.1, CACNA1G, CAC1G_HUMAN, KIAA1123, CaV T1, Cav3 1, cav3 1c, MGC117234, NBR13, voltage gated calcium channel cav3.1, calcium channel voltage dependent alpha 1G subunit, calcium channel voltage dependent T type alpha 1G subunit, calcium channel voltage dependent T type alpha1G subunit, voltage dependent calcium channel alpha 1G subunit isoform 11, voltage dependent T type calcium channel subunit alpha 1G, Voltage gated calcium
Application:
IHC, WB, IF, ICC
Concentration:
1 mg/ml
Species Reactivity:
Mouse
Purification:
Protein G Purified
Storage Conditions:
-20[o]C
Supplier:
StressMarq Biosciences
Host:
Mouse
Reactivities:
Human, Mouse, Rat
ABP:
IMP-GEN-2015-06 < 10% Serum <100ml
Buffer:
PBS pH7.4, 50% glycerol, 0.09% sodium azide
Immunogen:
Fusion protein amino acids 2052-2172 (cytoplasmic C-terminus) of mouse Cav3.1
Clone:
N178A/9 (Formerly sold as S178A-9)
Uniprot:
Q9WUT2
Synonyms:
[a]1G;a1;a1G;alpha-1G;Cav3.;Cav3.1d;mKIAA1123;voltage-dependent T-type calcium channel subunit alpha-1G
Extra Details:
Cav3.1, encoded by the CACNA1G gene, is a low-voltage-activated T-type calcium channel that plays a pivotal role in regulating neuronal excitability and rhythmic firing. Widely expressed across tissues, Cav3.1 is particularly important in the central nervous system, where it contributes to burst firing and oscillatory activity in thalamic and cortical neurons. In the heart, it may also participate in pacemaker currents, highlighting its physiological versatility. In the brain, Cav3.1 channels are considered secondary pacemakers, modulating sleep-wake cycles, sensory processing, and synaptic integration. Dysregulation of Cav3.1 activity has been implicated in a range of neurological and neurodegenerative disorders, including epilepsy, Parkinson's disease, and essential tremor. Altered T-type calcium channel function may also contribute to cognitive decline and neuroinflammation, positioning Cav3.1 as a potential therapeutic target in age-related neurodegeneration. Pharmacological blockers of T-type calcium channels, including Cav3.1, are already used clinically as antihypertensives and antiepileptics. Emerging evidence suggests these channels may also mediate the effects of certain anesthetics and antipsychotics, further underscoring their relevance in neuropharmacology. Despite their clinical significance, many aspects of Cav3.1's cellular localization, in vivo function, and disease-specific roles remain underexplored. Advancing our understanding of Cav3.1 could unlock new strategies for modulating calcium signaling in neurodegenerative disease.
Shipping Conditions:
Blue Ice